Show simple item record

dc.contributor.authorGrigorov, Hristo S.
dc.date.accessioned2017-09-20T15:57:43Z
dc.date.available2017-09-20T15:57:43Z
dc.date.issued2016
dc.identifier.citationChua, W. L. L., Grigorov, H. S. & Hiley, J. (2016). Oestrogen (adjunct) versus placebo for women with schizophrenia. Cochrane Database of Systematic Reviews, (6), pp.14.
dc.identifier.other10.1002/14651858.CD012220
dc.identifier.urihttp://hdl.handle.net/20.500.12904/9853
dc.description.abstractThis is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the clinical efficacy and safety of oestrogen as an adjunctive treatment versus placebo, in women with schizophrenia or schizophrenia-like illnesses. Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
dc.description.urihttp://onlinelibrary.wiley.com/doi/10.1002/14651858.CD012220/full
dc.formatFull text uploaded
dc.subjectSchizophrenia
dc.subjectDrug therapy
dc.titleOestrogen (adjunct) versus placebo for women with schizophrenia
dc.typeArticle
refterms.dateFOA2021-06-14T11:07:55Z
html.description.abstractThis is the protocol for a review and there is no abstract. The objectives are as follows: To evaluate the clinical efficacy and safety of oestrogen as an adjunctive treatment versus placebo, in women with schizophrenia or schizophrenia-like illnesses. Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.


Files in this item

Thumbnail
Name:
Chua 2016 1-16.pdf
Size:
238.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record